Does Indication-Specific Pricing Fit Generics With Carveouts?
By Michael Cottler and Natasha Daughtrey ( December 15, 2017, 12:03 PM EST) -- Indication-specific pricing (ISP) is often proposed as a solution to rising health care costs, particularly for branded drugs that have multiple indications. But it is unclear whether such a model could work with generic and biosimilar products that have labels from which one or more approved uses have been carved out....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.